These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

111 related items for PubMed ID: 8014839

  • 1. [Topoisomerase II mediated DNA strand cleavage and antitumor activities against murine leukemia P388 of novel acridines].
    Kimura M.
    Yakugaku Zasshi; 1994 May; 114(5):304-7. PubMed ID: 8014839
    [Abstract] [Full Text] [Related]

  • 2. Characterization of a subline of P388 leukemia resistant to amsacrine: evidence of altered topoisomerase II function.
    Per SR, Mattern MR, Mirabelli CK, Drake FH, Johnson RK, Crooke ST.
    Mol Pharmacol; 1987 Jul; 32(1):17-25. PubMed ID: 3037302
    [Abstract] [Full Text] [Related]

  • 3. [Antitumor agents targeting mammalian topoisomerases].
    Nakano H.
    Gan To Kagaku Ryoho; 1991 Aug; 18(10):1550-5. PubMed ID: 1651681
    [Abstract] [Full Text] [Related]

  • 4. DNA damage by antitumor acridines mediated by mammalian DNA topoisomerase II.
    Rowe TC, Chen GL, Hsiang YH, Liu LF.
    Cancer Res; 1986 Apr; 46(4 Pt 2):2021-6. PubMed ID: 3004716
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Topoisomerase II mediated DNA lesions induced by acridine-4-carboxamide and 2-(4-pyridyl)quinoline-8-carboxamide.
    Woynarowski JM, McCarthy K, Reynolds B, Beerman TA, Denny WA.
    Anticancer Drug Des; 1994 Feb; 9(1):9-24. PubMed ID: 8141968
    [Abstract] [Full Text] [Related]

  • 9. Antitumor drug cross-resistance in vivo in a cisplatin-resistant murine P388 leukemia.
    Waud WR, Harrison SD, Gilbert KS, Laster WR, Griswold DP.
    Cancer Chemother Pharmacol; 1991 Feb; 27(6):456-63. PubMed ID: 1849465
    [Abstract] [Full Text] [Related]

  • 10. Cross-resistance of an amsacrine-resistant human leukemia line to topoisomerase II reactive DNA intercalating agents. Evidence for two topoisomerase II directed drug actions.
    Zwelling LA, Mayes J, Hinds M, Chan D, Altschuler E, Carroll B, Parker E, Deisseroth K, Radcliffe A, Seligman M.
    Biochemistry; 1991 Apr 23; 30(16):4048-55. PubMed ID: 1850298
    [Abstract] [Full Text] [Related]

  • 11. Induction of mammalian DNA topoisomerase I and II mediated DNA cleavage by saintopin, a new antitumor agent from fungus.
    Yamashita Y, Kawada S, Fujii N, Nakano H.
    Biochemistry; 1991 Jun 18; 30(24):5838-45. PubMed ID: 1646001
    [Abstract] [Full Text] [Related]

  • 12. From amsacrine to DACA (N-[2-(dimethylamino)ethyl]acridine-4-carboxamide): selectivity for topoisomerases I and II among acridine derivatives.
    Finlay GJ, Riou JF, Baguley BC.
    Eur J Cancer; 1996 Apr 18; 32A(4):708-14. PubMed ID: 8695277
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Relative activity of structural analogues of amsacrine against human leukemia cell lines containing amsacrine-sensitive or -resistant forms of topoisomerase II: use of computer simulations in new drug development.
    Zwelling LA, Mitchell MJ, Satitpunwaycha P, Mayes J, Altschuler E, Hinds M, Baguley BC.
    Cancer Res; 1992 Jan 01; 52(1):209-17. PubMed ID: 1309224
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Effect of 1-beta-D-arabinofuranosylcytosine (ara-C) on nuclear topoisomerase II activity and on the DNA cleavage and cytotoxicity produced by 4'-(9-acridinylamino)methanesulfon-m-anisidide (m-AMSA) and etoposide in m-AMSA-sensitive and -resistant human leukemia cells.
    Bakic M, Chan D, Andersson BS, Beran M, Silberman L, Estey E, Ricketts L, Zwelling LA.
    Biochem Pharmacol; 1987 Dec 01; 36(23):4067-77. PubMed ID: 2825713
    [Abstract] [Full Text] [Related]

  • 20. Characterization of the biological and biochemical activities of F 11782 and the bisdioxopiperazines, ICRF-187 and ICRF-193, two types of topoisomerase II catalytic inhibitors with distinctive mechanisms of action.
    van Hille B, Etiévant C, Barret JM, Kruczynski A, Hill BT.
    Anticancer Drugs; 2000 Nov 01; 11(10):829-41. PubMed ID: 11142691
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.